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Effective therapies for the so-called atypical parkinsonian syndrome (APS) such as multiple
system atrophy (MSA), progressive supranuclear palsy (PSP), or corticobasal syndrome
(CBS) are not available. Dopamine agonists (DA) are not often used in APS because of
inefficacy and in a minority of case, their side effects, like dyskinesias, impairment of
extrapyramidal symptoms or the appearance of psychosis, and REM sleep behavioral dis-
orders (RBD). Transdermal rotigotine (RTG) is a non-ergot dopamine agonist indicated for
use in early and advanced Parkinson’s disease with a good tolerability and safety. Moreover,
its action on a wide range of dopamine receptors, D1, D2, D3, unlike other DA, could make
it a good option in APS, where a massive dopamine cell loss is documented. In this pilot,
observational open-label study we evaluate the efficacy and tolerability of RTG in patients
affected by APS. Thirty-two subjects with diagnosis of APS were treated with transdermal
RTG. APS diagnosis was: MSA parkinsonian type (MSA-P), MSA cerebellar type (MSA-
C), PSP, and CBS. Patients were evaluated by UPDRS-III, neuropsychiatric inventory, mini
mental state examination at baseline, and after 6, 12, and 18 months. The titration sched-
ule was maintained very flexible, searching the major clinical effect and the minor possible
adverse events (AEs) at each visit. AEs were recorded. APS patients treated with RTG show
an overall decrease of UPDRS-III scores without increasing behavioral disturbances. Only
three patients were dropped out of the study. Main AEs were hypotension, nausea, vom-
iting, drowsiness, and tachycardia. The electroencephalographic recording power spectra
analysis shows a decrease of theta and an increase of low alpha power. In conclusion,
transdermal RTG seems to be effective and well tolerated in APS patients.
Keywords: rotigotine, atypical parkinsonism, open-label study, safety, efficacy
INTRODUCTION
Atypical parkinsonian syndromes (APS) comprise mostly progres-
sive supranuclear palsy (PSP), corticobasal syndrome (CBS), and
multiple system atrophy (MSA) (1–5). Despite decades of research,
the cause and pathophysiology of atypical parkinsonian disorders
are still unknown. While a poor response to dopamine agonists
(DA) therapy is included as a criterion for MSA, PSP, and CBS, the
literature suggests that about one-third of patients with each of
the conditions does have a favorable response to the drug (6–8).
A recent review (9) has demonstrated that APS patients experi-
ence a response to dopaminergic therapy that is generally modest
and frequently transient. Also, all three conditions are similar
because dopaminergic treatment rarely induces involuntary move-
ments or mental status changes as well as RBD. Moreover, there
have been reports of worsening motor function in patients with
CBS, PSP, and MSA treated with dopaminergic therapy (9). As a
consequence, therapeutic options are still limited.
Rotigotine (RTG) is a non-ergolinic dopamine agonist admin-
istered via a transdermal patch that delivers the drug over a 24-h
period. (10). In six large, well designed clinical trials, RTG was an
efficacious treatment for Parkinson’s disease, improving morning
motor functioning, sleep disturbances, night-time motor symp-
toms, and depression. RTG was generally well tolerated across
the trials and in longer-term extension studies (11–19). Thus, the
RTG transdermal patch offers a novel therapeutical tool with effi-
cacy in reducing disabling motor and non-motor symptoms, and
acceptable tolerability profile.
To the best of our knowledge, transdermal RTG has been
administered only in patients with idiopathic Parkinson’s disease
but not in APS patients. Despite their different neuropathologi-
cal features, MSA, PSP, and CBS are unanimously recognized as
belonging to the nosographical category of the atypical parkin-
sonisms. Indeed, although MSA is an alpha-synucleinopathy and
PSP/CBS are tauopathies, they share as final common pathway the
degeneration of the dopaminergic system. The present observa-
tional trial has an eminently clinical approach. Indeed, the study
was designed to provide a practical therapeutic option to neurolo-
gists and physicians in general when facing atypical parkinsonian
syndromes. So, the further subdivision of the patients based on
the neuropathological substrate was beyond the scope of the study.
RTG could be a therapeutic option for APS because its mechanism
of action encompasses a wide dopamine receptors spectrum (from
D1 to D3), unlike other DA agents. Moreover, RTG patch could
have the advantage of a minor adverse events (AEs) rate and the
possibility to be administered in patients with swallowing prob-
lems. In the present study, RTG was administered to 32 patients
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Table 1 | Socio-demographical data of the whole study group; age and
education are expressed in years.
Subjects MMSE UPDRS/56 NPI/144 Age Education
32 20.3 36.1 56.4 69.4 6.1
with APS, showing an overall good performance on the motor
symptoms, without inducing behavioral or extrapyramidal AEs.
MATERIALS AND METHODS
SUBJECTS
Thirty-two subjects with diagnosis of atypical parkinsonian disor-
ders were admitted to our National Institute for Research and Cure
of Neurodegenerative Disorders Fatebenefratelli (FBF) in Brescia
and treated with transdermal RTG. Subjects were evaluated by
DVM, a board-certified neurologist and movement disorders spe-
cialist who works in the Memory Clinic and Movement Disorders
Center. All experimental protocols had been approved by the local
ethics committee. Informed consent was obtained from all par-
ticipants or their caregivers, according to the Code of Ethics of
the World Medical Association (Declaration of Helsinki). Table 1
shows socio-demographical data of the whole study group.
DIAGNOSTIC CRITERIA
In our subjects, diagnosis was as follows: MSA-P (11), MSA-C (4),
PSP (7), and CBS (10). Moreover, all diagnoses were performed
exclusively on clinical evaluation. Diagnostic criteria of atypical
parkinsonism were inferred from the most diffuse guidelines and
clinical criteria (20–30). Briefly, the classical PSP phenotype is
characterized by postural instability and early falls, early cognitive
dysfunction, and abnormalities of vertical gaze; it is referred to as
Richardson’s Syndrome (RS). PSP was recently divided clinically
and pathologically into two main phenotypes: classical PSP-RS and
PSP-parkinsonism (PSP-P), the latter characterized by an asym-
metric onset, tremor and moderate initial therapeutic response to
levodopa (2, 29). In this study, the subjects affected by PSP were
all classical PSP-RS type. The classical CBS phenotype consists
of asymmetric parkinsonism, cortical signs (e.g., apraxia, cortical
sensory loss, and alien limb), and possibly other signs such as dys-
tonia and myoclonus; it is referred to as CBS. A recent study (29)
proposed new criteria for probable and possible CBS. Probable
CBS criteria require insidious onset and gradual progression for
at least 1 year, age at onset ≥50 years, no similar family history or
known tau mutations, and a clinical phenotype of CBS. The pos-
sible CBS category uses similar criteria but has no restrictions on
age or family history, allows tau mutations, permits less rigorous
phenotype fulfillment, and includes a PSP phenotype. Among our
patients, seven met probable and three met possible CBS criteria.
MSA is typically characterized by parkinsonism, autonomic dys-
function, and a combination of cerebellar and pyramidal signs.
MSA is classified according to the predominant phenotype at
onset into MSA-parkinsonism or (MSA-P), or MSA of the cere-
bellar type (MSA-C). Up to 80% of the patients develop most
of the characteristic features during the course of the disease.
The main concomitant pathologies of the patients in the study
sample were: hypertension, hypercholesterolemia, hypertensive
cardiopathy, diabetes mellitus type II, and carotid atheroma. As
a consequence, patients were taking antihypertensive, antiplatelet,
and antidiabetic drugs. The patients were encouraged to maintain
as stable as possible the concomitant treatments. Patients who
presented psychosis were not admitted to the study.
CLINICAL EVALUATION
All patients underwent a complete physical and neurological
examination. All patients underwent an electroencephalographic
recording (EEG), and magnetic resonance imaging (MRI). Only
20 patients underwent single photon emission computed tomog-
raphy with dopamine transporter scan (SPECT-dat scan). MRI
was useful to exclude vascular parkinsonism, whereas SPECT
shows diffuse and more symmetric degeneration of nigrostriatal
pathways, excluding idiopathic Parkinson’s disease. Patients were
assessed by the 56 points unified Parkinson’s disease rating scale
(UPDRS) part III (31), neuropsychiatric inventory (NPI) (32),
and mini mental state examination (MMSE) (33). More disease-
specific scales are available to assess APS, like the Unified Multiple
System Atrophy Rating Scale (UMSARS) (34) or the Progressive
Supranuclear Palsy Rating Scale (PSPRS) (35) as well as the Scales
for Outcomes in Parkinson’s disease-Autonomic (SCOPA-AUT)
(36) or the movement disorders society modified UPDRS (MDS-
UPDRS) (37). Anyway, the UPDRS scale has been chosen because
it is well known and widespread. As a consequence, the general
confidence of neurologists and physicians with this scale is very
high. Moreover, it has the advantage that the results obtained are
easily comparable with previous and future studies. Of note, a
recent review (38) has convincingly demonstrated that the UPDRS
is a reliable tool in the assessment of atypical parkinsonism. Evalu-
ations were performed at baseline (T0) and during each follow-up.
The follow-up visits were performed after 6, 12, and 18 months
(T6, T12, and T18). The titration schedule was maintained very
flexible, searching the major clinical effect and the minor possible
AEs at each visit. When possible, the dosage was increased by 2 mg
every 6 months. All AEs were recorded.
EEG RECORDINGS
The EEG activity was recorded continuously from 19 sites by using
electrodes set in an elastic cap (Electro-Cap International, Inc.)
and positioned according to the 10–20 international systems (Fp1,
Fp2, F7, F3, Fz, F4, F8, T3, C3, Cz, C4, T4, T5, P3, Pz, P4, T6,
O1, and O2). In order to keep constant the level of vigilance, an
operator controlled on-line the subject and the EEG traces, alert-
ing the subject any time there were signs of behavioral and/or
EEG drowsiness. The ground electrode was placed in front of Fz.
The left and right mastoids served as reference for all electrodes.
The recordings were used off-line to re-reference the scalp record-
ings to the common average. Re-referencing was done prior to
the EEG artifact detection and analysis. Data were recorded with
a band-pass filter of 0.3–70 Hz, and digitized at a sampling rate
of 250 Hz (BrainAmp, Brain Products, Germany). Electrodes-skin
impedance was set below 5 kHz. Horizontal and vertical eye move-
ments were detected by recording the electrooculogram (EOG).
The recording lasted 5 min, with subjects with closed eyes. Longer
recordings would have reduced the variability of the data, but
they would also have increased the possibility of slowing of EEG
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oscillations due to reduced vigilance and arousal. EEG data were
then analyzed and fragmented off-line in consecutive epochs of
2 s, with a frequency resolution of 0.5 Hz. The average number of
epochs analyzed was 140, ranging from 130 to 150. The epochs with
ocular, muscular, and other types of artifacts were discarded by
two skilled electroencephalographists (39). EEG recordings were
performed at baseline as well as at each of the follow-up control
visits.
ANALYSIS OF INDIVIDUAL FREQUENCY BANDS
All recordings were obtained in the morning with subjects rest-
ing comfortably. Vigilance was continuously monitored in order
to avoid drowsiness. A digital FFT-based power spectrum analysis
(Welch technique, Hanning windowing function, no phase shift)
computed – ranging from 2 to 45 Hz – the power density of EEG
rhythms with a 0.5 Hz frequency resolution. Two anchor frequen-
cies were selected according to the literature guidelines, that is, the
theta/alpha transition frequency (TF) and the individual alpha fre-
quency (IAF) peak. These anchor frequencies were computed on
the power spectra averaged across all recording electrodes. The TF
marks the TF between the theta and alpha bands, and represents
an estimate of the frequency at which the theta and alpha spectra
intersect. TF was computed as the minimum power in the alpha
frequency range, since our EEG recordings were performed at rest.
The IAF represents the frequency with the maximum power peak
within the extended alpha range (5–14 Hz). Based on TF and IAF,
we estimated the frequency band range for each subject, as follows:
delta from TF-4 to TF- 2, theta from TF-2 to TF, low alpha band
from TF to IAF, and high alpha band from IAF to the point of the
minimum power after the IAF values. The mean frequency range
computed in MCI subjects considered as a whole are: delta 2.9–
4.9 Hz; theta 4.9–6.9 Hz; low alpha1 6.9–10.9 Hz; and high alpha2
8.9–11.9 Hz. Finally, in the frequency bands determined on an
individual basis, we computed the relative power spectra for each
subject. The relative power density for each frequency band was
computed as the ratio between the absolute power and the mean
power spectra from 2 to 45 Hz. The relative band power at each
band was defined as the mean of the relative band power for each
frequency bin within that band (39).
STATISTICAL ANALYSIS
One-way analysis of variance (ANOVA), with Newman–Keuls
post hoc correction, was performed to test the changes in MMSE,
UPDRS-III, and NPI considering all the evaluations (T0, T6, T12,
and T18). Also analysis of EEG results has been performed with
ANOVA.
RESULTS
Table 2 summarizes the main results.
At baseline, mean UPDRS-III score was 36.1/56, mean NPI
score was 56.4/144, mean MMSE score was 20.3/30. 29/32 (90.7%)
patients has reached 6 months of treatment with RTG (mean
dose= 3.2 mg/24 h); mean UPDRS-III score was 28.6/56, mean
NPI score 50.1/144, mean MMSE score 19.3/30. Three patients
were dropped out for AEs. 23/32 (71.8%) patients has reached
12 months of treatment with RTG (mean dose= 3.7 mg/24 h),
mean UPDRS-III score was 26.5/56, mean NPI score was 41.2/144,
mean MMSE score was 18.1/30. No patient more was dropped out
for AEs at 12 months follow-up. 16/32 (50%) patients completed
18 months of treatment with RTG (mean dose= 4.4 mg/24 h)
mean UPDRS-III score was 25.5/56, mean NPI score was 35.9/144,
mean MMSE score was 15.3/30. No patient was dropped out at
18 months follow-up (Table 2). Reported AEs were: hypotension
(five patients), nausea (four), vomiting (three), drowsiness (two),
and tachycardia (one). On the whole, 15 patients were affected by
transient AEs (46.8%) and only 3 patients suspended RTG treat-
ment due to AE (9.3%; vomiting, tachycardia, and sleepiness).
No heart congestion failure was detected among our patients.
All other patients are yet in the study, although with different
follow-up.
Figure 1 shows the ANOVA results for UPDRS-III. A significant
decrease of the score (p< 0.005) was found. In post hoc analysis,
all the comparisons with the baseline were statistically significant
(p< 0.02).
Figure 2 shows the ANOVA results for NPI. A significant
decrease of the score (p< 0.03) was found. In post hoc analysis,
all the comparisons with the T18 follow-up were statistically sig-
nificant (p< 0.04). Moreover, the evaluation at T12 was significant
as compared to the baseline (p< 0.05).
Table 2 | Number of subjects and clinical characteristics at baseline
andT6,T12, andT18 follow-up (between the brackets the number of
subjects dropped out).
T0 T6 T12 T18
Subjects 32 29 (3) 20 (0) 13 (0)
MMSE 20.3 19.3 18.1 15.3
UPDRS 36.1 28.6 26.5 25.5
NPI 56.4 50.1 41.2 35.9
RTG dosage n.d. 3.2 3.7 4.4
FIGURE 1 | ANOVA results for UPDRS score.
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FIGURE 2 | ANOVA results for NPI score.
FIGURE 3 | ANOVA results for MMSE score.
Figure 3 shows the ANOVA results for MMSE. A significant
decrease of the score (p< 0.05) was found. In post hoc analysis, the
comparison between baseline evaluation and the T18 follow-up
was statistically significant (p< 0.01).
The power spectra show a significant decrease of theta and
increase of low alpha band but no for high alpha power. These
results were present at the 6-month (theta p< 0.001, low alpha
p< 0.002, high alpha p= 0.09) follow-up and were maintained
at both the 12-month follow-up (theta p< 0.002, low alpha
p< 0.001, high alpha p= 0.08) and the 18-month follow-up (theta
p< 0.004, low alpha p< 0.005, high alpha p= 0.09).
DISCUSSION
PRELIMINARY REMARKS
From an heuristic point of view, a more focused analysis, split-
ting the groups for single pathology, or including at least the
separation of MSA from PSP and CBS, would be methodolog-
ically correct. Anyway, it is well known that, in the early stage
of the disease, the differentiation of the various forms of atyp-
ical parkinsonian disorders can be challenging. In some cases,
PSP presents with features of CBS, including apraxia, alien limb
phenomena, and cortical sensory loss (40). Most PSP, but also
some MSA cases, present with early falls and supranuclear vertical
gaze palsy (26). Early autonomic dysfunctions including urinary
urgency, frequency or nocturia without hesitancy, chronic consti-
pation, postural hypotension, sweating abnormalities, and erectile
dysfunction are reasonable discriminators of MSA but could be
present in PSP or CBS (3, 41–44). As a consequence, the first need
of neurologists and physicians in the clinical practice is to find a
safe and possibly efficacious treatment for atypical parkinsonisms
considered as a whole. Nonetheless, we claim that further studies
will assess the remaining controversial aspects in APS diagnosis to
find targeted therapies according to the neuropathological alter-
ations. In the present study, we try to provide a suitable treatment
option in a very poor therapeutic context.
CURRENT TREATMENT OPTIONS IN ATYPICAL PARKINSONIAN
SYNDROME
Although there are still no treatments available for the spo-
radic atypical parkinsonian conditions, important efforts have
been done in recent years, which, even if not proven effective
clinically, will certainly guide further research. A randomized,
placebo-controlled clinical trial to assess the effects of treatment
with the monoamine oxidase-B inhibitor rasagiline (1 mg/day)
for 48 weeks in 174 patients with possible or probable MSA-
Parkinsonism type, in 39 sites in 12 countries, found no significant
difference in progression in the total UMSARS score between
the verum and placebo groups (45). A single-arm, single-center,
open-label pilot trial evaluated monthly infusions of 0.4 g/kg intra-
venous immunoglobulin for 6 months in seven patients as an
anti-inflammatory approach, and found significantly improved
UMSARS part I (activities of daily living) and II (motor func-
tions); verification in a controlled study was proposed (46). A
recent study compared 30–50 intraarterial or intravenous injec-
tions of autologous mesenchymal stem cells (MSCs) vs. placebo
in 33 patients with probable MSA-cerebellar type and suggested
that the MSC group had a smaller increase in total and part II
UMSARS scores from baseline throughout a 360-day follow-up
period; as the mechanism of action of this intervention remains
unclear, a careful experimental and clinical re-evaluation of these
findings should be considered (47).
In regard to PSP, a multinational phase 2/3 randomized,
double-blind, placebo-controlled trial enrolled 313 participants,
to be treated with 30 mg davunetide or placebo twice daily for
52 weeks at 47 sites, and found no significant effect on the
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co-primary outcome measures, the PSPRS and the Schwab and
England Activities of Daily Living (SEADL) (Press release Decem-
ber 18, 2012 by Allon Therapeutics, www.allontherapeutics.com).
An open-label pilot trial of lithium, an inhibitor of glycogen
synthase kinase-3 (GSK-3), in individuals with PSP or CBS (Clin-
icalTrials.gov Identifier NCT00703677) recruited 17 patients and
was stopped prematurely because the majority of participants did
not tolerate the study drug. A multinational, phase II, double-
blind, placebo-controlled trial enrolled 142 patients with PSP,
who were treated orally with tideglusib (600 or 800 mg p.d.),
also a GSK-3 inhibitor, or placebo for 1 year. There were no
significant differences between the high dose, low dose, and
either dose groups vs. the placebo group in the primary clini-
cal outcome measures. A subset of 37 patients underwent base-
line and 52-week MRI; this substudy demonstrated significantly
reduced global brain atrophy in tideglusib-treated patients (48).
The effect of GSK-3 inhibition in PSP thus warrants further
investigation (49).
TRANSDERMAL RTG AS TREATMENT OPTION FOR ATYPICAL
PARKINSONIAN SYNDROME
Transdermal RTG seems to be effective and well tolerated in
patients with APS. Our results show significant improvement in
UDPRS-III scores, maintained along the course of the 18 months
follow-up. Moreover, only 3 patients were dropped out and 15
patients were affected by transient AEs. A plausible explanation of
the results is that RTG transdermal patch has a wider dopaminergic
profile action as compared to other non-ergot, prolonged-release
DA, allowing a more diffused reply therapy, covering the impotent
dopaminergic loss in atypical parkinsonism (50). Indeed, RTG has
a dopaminergic agonist action on D1, D2, D3 dopamine receptors,
unlike pramipexole (D3 agonist) and ropinirole (D2/D3 agonist).
Our results show also a reduction of NPI scores, which became
significant at the T12 and T18 follow-up evaluation. Previously, it
has been demonstrated that RTG was efficacious in reducing sleep
disturbance and other non-motor symptoms in PD patients (51,
52). This safety profile could be explained by the particular mech-
anism of action of RTG. RTG is a non-ergolinic dopamine agonist
with direct actions at dopamine receptors (D1–3) (53). Of note,
RTG has its highest affinity for and activity at D3 receptors (53). D3
receptors are sparse in the caudate–putamen region, but densely
populated in ventral striatum and appear to play a modulatory
role on motor output and the affective state (53). RTG also had
affinity to non-dopaminergic receptors, such as α2B-adrenergic
receptors and serotonin 5-HT1A receptors that could positively
modulate mood and behavior. The duration of the therapeutic
effect on both motor and behavioral symptoms until 18 months
of follow-up could suggest a neuroprotective effect. Although pre-
viously seen in animal models and in vitro studies (54), this aspect
needs to be cautious and further assessments. During the study,
our patients did not suffer from congestive heart failure. Of note,
RTG had low affinity for serotonin 5-HT2B receptors which may
be of clinical importance, as ergolinic DA thought to cause car-
diac valvular damage are full or partial serotonin 5-HT2B receptor
agonists (55, 56).
Our results show no positive effect on cognitive status.
Anyway, the MMSE score shows that patients were highly
cognitively impaired, on average, at the beginning of the study.
Further studies, with less initially cognitively compromised
patients and grouped for single pathologies, will better clarify
this issue.
EEG OSCILLATORY ACTIVITY
Our results confirm previous works showing that the most
significant finding in Parkinson’s disease synchronized oscillatory
activity is the prevalence of a rhythmic activity in the range of
4–7 Hz, usually termed theta band. This activity is characteris-
tic of the basal ganglia-thalamocortical circuits, and such activity
can be reduced by dopaminergic treatments (57). The increase
of the low alpha activity could be explained by the relief of
large thalamo-cortical circuits, in particular the loop involving
higher order brain areas, typically entrained by the alpha rhythm.
On the contrary, the lack of effect on high alpha oscillatory
activity could suggest a poor effect on cortico-cortical connec-
tions, which gave their contribution on the upper alpha rhythm
component.
STUDY LIMITATIONS
This study is a pilot, open-label, observational study with a clear
explorative purpose. First of all, we have to remark that small
sample size has not made possible the investigation on the single
pathology level because of the lack of any statistical power. Of note,
the results could not be extended to other conditions such as the
primary progressive freezing of gait preceding the PSP, because we
have not investigated such phenotype. As a consequence, further
randomized, double-blind, placebo-controlled trial studies with
a bigger sample size and with more disease-specific scales and
assessment for both the daily living functionality and the statisti-
cal evaluation are needed to confirm the present results. Anyway,
the favorable outcomes could be very useful as a practical guideline
to help clinicians and neurologists to find a treatment in atypical
parkinsonisms.
CONCLUSION
In our observational, open-label study, RTG appears to be a suit-
able therapy in APS patients as it has a good tolerability and efficacy
profile. The activation of D1–D2–D3 receptor in the caudate–
putamen region by RTG patch, compensates for the spread loss of
dopaminergic function in these areas and could be responsible for
the efficacy of this drug. Anyway, more studies are mandatory to
confirm the results.
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